Valuation: Trinity Biotech plc

Market Cap 5.52M 4.95M 4.58M 4.15M 7.75M 526M 7.84M 54.76M 21.81M 275M 20.72M 20.28M 874M P/E 2024
-0.48x
P/E 2025 -0.39x
Enterprise Value 138M 124M 115M 104M 194M 13.18B 197M 1.37B 547M 6.9B 519M 508M 21.89B EV / Sales 2024
1.8x
EV / Sales 2025 3.37x
Free-Float
96.2%
Yield 2024 *
-
Yield 2025 -
1 day-4.90%
1 week-12.26%
Current month+5.75%
1 month+1.19%
3 months-45.38%
6 months-63.01%
Current year-71.34%
1 week 6.69
Extreme 6.69
7.8
1 month 5.01
Extreme 5.01
8.77
Current year 5.01
Extreme 5.01
28.87
1 year 5.01
Extreme 5.01
52.5
3 years 5.01
Extreme 5.01
106.5
5 years 5.01
Extreme 5.01
315
10 years 5.01
Extreme 5.01
1,110
Manager TitleAgeSince
Chief Executive Officer 45 17/12/2023
Director of Finance/CFO - 23/12/2025
Chief Operating Officer - 01/01/1997
Director TitleAgeSince
Chairman 70 01/05/1995
Director/Board Member 45 -
Director/Board Member - 29/09/2023
Date Insider Type Main position Quantity % Market Cap. Importance
18/03/26 Other

Chief Executive Officer

980,837 1.1731%
18/03/26 Other

Chief Executive Officer

10,000 0.0120%
18/03/26 Other

Director

70,004 0.0837%
Change 5-day change 1-year change 3-year change Capi.($)
-4.90%-12.26%-77.33%-89.93% 5.81M
-0.45%+2.12%-18.93%+10.54% 178B
+0.86%+2.15%-19.13%+16.07% 116B
+0.88%+1.88%+1.66%+36.51% 115B
-2.26%+2.24%-44.03%+5.76% 93.1B
-0.31%-4.72%-3.36%+72.86% 62.09B
-0.09%+0.11%+10.71%+84.36% 55.87B
+0.07%+0.42%+5.94%-22.43% 53.12B
+0.30%+1.70%-11.26%+43.83% 44.22B
+0.10%+3.08%-3.06%-8.71% 33.59B
Average -0.57%+1.22%-15.88%+14.89% 75.1B
Weighted average by Cap. -0.12%+2.37%-12.51%+24.19%

Financials

2024 2025
Net sales 61.56M 55.23M 51.06M 46.24M 86.39M 5.86B 87.44M 610M 243M 3.07B 231M 226M 9.74B 43.78M 39.28M 36.32M 32.89M 61.45M 4.17B 62.2M 434M 173M 2.18B 164M 161M 6.93B
Net income -31.79M -28.52M -26.37M -23.88M -44.62M -3.03B -45.16M -315M -126M -1.58B -119M -117M -5.03B -37.38M -33.53M -31M -28.08M -52.46M -3.56B -53.09M -371M -148M -1.86B -140M -137M -5.91B
Net Debt 95.6M 85.77M 79.3M 71.82M 134M 9.1B 136M 948M 378M 4.76B 359M 351M 15.12B 133M 119M 110M 99.8M 186M 12.65B 189M 1.32B 525M 6.62B 499M 488M 21.02B
Projected Income Statement - Annual - Trinity Biotech plc
Logo Trinity Biotech plc
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Employees
287
Date Price Change Volume
28/10/26 $6.790 -5.03% 10,677
27/10/26 $7.150 +0.54% 1,855
26/10/26 $7.112 -2.57% 14,678
23/10/26 $7.299 -2.81% 14,683
22/10/26 $7.510 -3.10% 4,743

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Trinity Biotech plc
  1. Stock Market
  2. Stocks
  3. TRIB Stock